Avandia Advisory Committee: Can Poking Old Wounds Be Good For FDA?

Two advisory panels will revisit the question of whether FDA should withdraw GlaxoSmithKline’s Avandia from the market as a reevaluation of the cardiovascular trial produces results similar to the original findings; the data does not seem to offer much more clarity, but does give the agency a chance to argue it handled previous controversies well.

FDA has placed itself it the unusual position of revisiting a regulatory decision well after making a lifecycle-altering change to a product’s marketing. Fortunately for the agency, the data that will be discussed at the June 5-6 advisory committee review of the safety of GlaxoSmithKline PLC’s diabetes drug Avandia appears very similar to the information considered by the agency in 2010 when it decided to keep the drug on the market with restrictions.

Re-adjudication of the open-label RECORD study by the Duke Clinical Research Institute (DCRI) has produced results similar to the original findings for Avandia (rosiglitazone) Also see "Avandia RECORD Study Re-Analysis To Get FDA Committee Scrutiny" - Pink Sheet, 12 April, 2013.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America